Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats

Cell Biology International
Gang XuYan-Jun Zeng

Abstract

Glioma is the most common primary intracranial malignant tumor. Despite advances in surgical techniques and adjuvant radio- and chemotherapies, the prognosis for patients with glioma remains poor. We have explored the effects of using genetically modified mesenchymal stem cells (MSCs) to treat malignant glioma in rats. Mesenchymal stem cells isolated from Sprague-Dawley rats can directly suppress the growth of C6 cells in vitro. MSCs transplanted intratumorally can also significantly inhibit the growth of glioma and prolong survival in C6 glioma-bearing models. MSCs producing Interleukin-18 infected by adenoviral vector inhibited glioma growth and prolonged the survival of glioma-bearing rats. Transplantation of IL-18 secreting MSCs was associated with enhanced T cell infiltration and long-term anti-tumor immunity. Thus, IL-18 may be an effective adoptive immunotherapy for malignant glioma. When used in conjunction with MSCs as targeting vehicles in vivo, IL-18 may offer a promising new treatment option for malignant glioma.

References

May 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·D L ShawlerH Fakhrai
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·M KohyamaT Ohno
Apr 2, 1999·Science·M F PittengerD R Marshak
Jun 5, 1999·Cellular and Molecular Life Sciences : CMLS·G J MaestroniP Galli
Nov 9, 2000·Proceedings of the National Academy of Sciences of the United States of America·K S AboodyE Y Snyder
Apr 30, 2003·Cancer Gene Therapy·Vincenza BarresiDaniele Filippo Condorelli
Aug 6, 2003·Annals of Surgical Oncology·Oliver StoeltzingLee M Ellis
Mar 9, 2004·Postȩpy higieny i medycyny doświadczalnej·Marek Fol, Teresa Gościcka
Nov 4, 2004·Journal of the National Cancer Institute·Matus StudenyMichael Andreeff
Dec 29, 2004·Annals of Neurology·Khalid ShahXandra O Breakefield
Mar 18, 2005·Cancer Science·Hirofumi HamadaYoshiro Niitsu
Jun 4, 2005·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Seok-Gu KangJoon Ki Kang
Sep 2, 2005·Vaccine·Deborah J MarshallLinda A Snyder
Oct 11, 2005·Neuro-oncology·Oliver HeeseKatrin Lamszus
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yasushi InoTomoki Todo
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael J RobertsonMohammed M Dar
Nov 1, 2003·Expert Review of Neurotherapeutics·Moneeb EhteshamJohn S Yu

❮ Previous
Next ❯

Citations

Jul 18, 2012·Bulletin of Experimental Biology and Medicine·V P BaklaushevV P Chekhonin
Mar 16, 2012·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Margaret F BennewitzErik M Shapiro
Apr 22, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Daniel BexellJohan Bengzon
Sep 10, 2010·Human Gene Therapy·Conrad P HodgkinsonVictor J Dzau
Jul 31, 2010·Stem Cells and Development·Sabino CiavarellaFranco Silvestris
Dec 15, 2011·Neuro-oncology·Emanuela Binello, Isabelle M Germano
Feb 2, 2010·Journal of Neuroinflammation·Silvia AlboniBruno Conti
Dec 15, 2010·Future Oncology·Erik Hp van PuttenMartine Lm Lamfers
Sep 2, 2014·Nature Reviews. Cancer·Daniel W Stuckey, Khalid Shah
Nov 10, 2010·Expert Opinion on Biological Therapy·Timothy J MyersAnna Spagnoli
Feb 24, 2016·Bulletin of Experimental Biology and Medicine·A N GabashviliV P Chehonin
Sep 29, 2011·Neuroscience Letters·Qianfa LongZhou Fei
Sep 10, 2015·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Brigitte AnlikerMatthias Schweizer
Mar 27, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Antonella MangravitiHenry Brem
Aug 14, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Bing HuangJian-Qing Gao
Jun 3, 2015·Bulletin of Experimental Biology and Medicine·A N GabashviliV P Chekhonin
Mar 20, 2013·Biomatter·Marta CompteLuís Alvarez-Vallina
Mar 18, 2015·Experimental and Therapeutic Medicine·Xiaoyi LiuZhigang Yu
Dec 20, 2011·World Journal of Stem Cells·Xu-Yong SunLong-Jun Dai
May 6, 2017·Journal of Cellular Physiology·Hamed MirzaeiMahmoud R Jaafari
Aug 5, 2010·Science Progress·Pedro Cesar ChagastellesMelissa Camassola
Aug 4, 2011·Nature Reviews. Neuroscience·Manfred Westphal, Katrin Lamszus
May 19, 2009·Expert Review of Anticancer Therapy·Thomas KosztowskiAlfredo Quiñones-Hinojosa
Jun 9, 2019·The Journal of Pharmacology and Experimental Therapeutics·Shen ChengSwayam Prabha
Oct 27, 2017·Oncotarget·Billy Samuel HillAntonella Zannetti
Mar 17, 2015·Advanced Healthcare Materials·Perry T YinKi-Bum Lee
Jun 17, 2020·Stem Cells Translational Medicine·Adriana BajettoTullio Florio
Nov 10, 2013·Cancers·Aneta KwiatkowskaMariano S Viapiano
Feb 13, 2016·Oncology Letters·Hiroki NambaTomohiro Yamasaki
Mar 8, 2019·Nature Reviews. Cancer·Rajendra Karki, Thirumala-Devi Kanneganti
Jul 1, 2010·Experimental and Therapeutic Medicine·Yun GaoHiroki Namba
Sep 27, 2018·Gene Therapy·Wei WeiWei Wang
May 20, 2021·CNS Oncology·Anda-Alexandra CalinescuSue K O'Shea
Mar 19, 2019·ACS Applied Materials & Interfaces·Alexander S TiminBoris V Afanasyev
Jul 16, 2011·Molecular Pharmaceutics·Marina CihovaCestmir Altaner
Aug 15, 2020·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Rawan Al-KharbooshAlfredo Quiñones-Hinojosa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.